We focus on engineering immune cells and modulating inflammatory and metabolic pathways to precisely control immune responses in chronic inflammation, metabolic disorders, and age-related diseases, including atherosclerotic cardiovascular disease. By integrating nano-immunotherapy, RNA-based gene therapies, and genetic regulation, we develop targeted strategies to reprogram pathogenic immune cells directly within diseased tissues. Our goal is to restore immune, inflammatory, and metabolic homeostasis while minimizing systemic toxicity and off-target effects.